GlassScriptPhysician profile
Susan E Marcotte
NPI 1184678377
$9,744.66
in general payments reported to CMS, 2019-2025
39 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,693 · 2020: $1,086 · 2021: $656 · 2022: $1,723 · 2023: $1,691 · 2024: $1,470 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,412 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,412.04 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,283.85 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,110.35 | 2019-2025 | |
| Amgen INC. | $824.10 | 2019-2025 | Prolia, Evenity, Repatha |
| Pfizer INC. | $781.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $470.45 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $454.12 | 2019-2022 | |
| Glaxosmithkline, LLC. | $427.54 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $411.37 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $400.61 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.04 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $296.78 | 2019-2024 | Veozah |
| Nestle Healthcare Nutrition INC. | $290.43 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $289.36 | 2024 | |
| Phathom Pharmaceuticals, INC. | $273.80 | 2024-2025 | Voquezna |
| Allergan, INC. | $215.25 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Marcotte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.